Bristol-Myers inks research deal with Tibotec for Daclatasvir
The collaboration is intended to evaluate the utility of Daclatasvir (BMS-790052), Bristol-Myers Squibb’s investigational NS5A replication complex inhibitor, along with Tibotec Pharmaceuticals’ NS3 protease inhibitor, TMC435, for the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.